Headlines about Bellicum Pharmaceuticals (NASDAQ:BLCM) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.0206180612103 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities research analysts have recently issued reports on BLCM shares. Jefferies Group reissued a “buy” rating and set a $16.00 target price on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Finally, BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $26.20.
Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $9.53 on Friday. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $17.00.
In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,206 shares of the stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 18.77% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Bellicum Pharmaceuticals (BLCM) Getting Somewhat Favorable Press Coverage, Analysis Finds” was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://weekherald.com/2017/12/09/bellicum-pharmaceuticals-blcm-getting-somewhat-favorable-press-coverage-analysis-finds.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.